Allergy

Three-year PIONEER data show avapritinib provides lasting symptom relief in indolent systemic mastocytosis with good safety.

An online course, AllergyAware, significantly improved school personnel’s ability to recognize and manage anaphylaxis.

A new study found patients with HS are significantly more likely to develop new-onset depression and anxiety, regardless of disease severity.

A randomized trial found pharmacist-led counseling improved allergic rhinitis symptom control but did not enhance adherence, knowledge, or quality of life.

New research finds patients with severe allergic asthma had greater emotional regulation than those with venom anaphylaxis, despite reporting poorer physical well-being.

In children with mild immediate or delayed reactions, direct drug provocation testing may eliminate the need for painful skin tests, according to new data from Türkiye.

Study finds monthly HAE attacks dropped from 54% to 9.8% after 3 years of lanadelumab, with improved quality of life and reduced severity.

The National Institute for Health and Care Excellence endorses betula verrucosa for long-term relief from severe birch tree allergies, such as allergic rhinitis or conjunctivitis.

Patients with hereditary angioedema who switched to donidalorsen saw significantly fewer attacks and improved disease control. The FDA decision expected in August 2025.

An audio recap of the top 5 stories in healthcare news from the week of 06/30-07/06.

Stay updated with the latest healthcare breakthroughs, including FDA news, clinical trial data, and regulatory submissions, in this week's essential news roundup.

Shaker shares how allergist-immunologists can use brief CBT, motivational interviewing, and risk reframing to shift patients’ fear of their food allergies into confidence.

KalVista's therapy is now approved under the name Ekterly, the first oral therapy for hereditary angioedema, empowering patients with timely, on-demand treatment options.

Key FDA approvals, clinical trial insights, and expert commentary in allergy care from the first half of 2025.

Q2 2025 allergy news highlights include FDA actions on HAE therapies, warnings for antihistamines, and new sinus surgery guidelines for chronic rhinosinusitis.

A review of the 16 novel drugs approved by the US Food and Drug Administration during the first half of 2025, with links to coverage from MJH Life Sciences publications.

This month in review captures 5 allergy news in June, from FDA approvals to phase 3 data.

Discover groundbreaking FDA approvals in 2025 that redefine treatment standards, enhance patient care, and address critical public health needs.

Chang explains the importance of collaboration between gastroenterologists and allergists in EoE care and praises recent ACG guidelines on disease management.

Although limited, recent research has indicated overall positive results of dupilumab in both reducing severe exacerbations and lowering risk of control loss.

New research has indicated increased food tolerance thresholds and desensitization from omalizumab and other biologics in comparison to placebo with no serious adverse effects.

With the FDA acceptance of the NDA, the agency has assigned a PDUFA target action date of January 31, 2026, and may require an Advisory Committee meeting for approval.

The monoclonal antibody garadacimab-gxii offers once-monthly, citrate-free dosing to prevent hereditary angioedema attacks in patients aged ≥ 12 years.

This interview with Singh highlights her conference presentation on allergy and its connection to pediatric atopic dermatitis.

A recent study reveals no link between cesarean delivery and childhood allergies, challenging previous findings and highlighting Japan's unique health context.